# Eptifibatide (Integrilin)

> GP IIb/IIIa inhibitor cyclic peptide for ACS and PCI.

Source: https://peptides.cafe/peptide/eptifibatide
Category: Antiplatelet · Cardiology
Tag: FDA-Approved · Cardiology

## Mechanism
Cyclic heptapeptide derived from rattlesnake venom that reversibly blocks platelet glycoprotein IIb/IIIa receptors, preventing fibrinogen binding and platelet aggregation.

## Research areas
- Acute coronary syndromes
- PCI

## Common research protocols
- ACS/PCI: 180 mcg/kg IV bolus + 2 mcg/kg/min infusion.

## Study summaries
- "PURSUIT trial" — NEJM (1998): Reduced death/MI in non-ST-elevation ACS.

## Considerations
- FDA-approved.
- Bleeding risk; renal adjustment required.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.